Quizartinib (AC220) br Fig Hemolytic activity a
Fig. 6. Hemolytic activity (a) of Alg-PDA materials with erythrocyte stock in PBS. Proliferation of MCF-10A Quizartinib (AC220) seeded on 3D-printed Alg, Alg-PDA, and 48-well plate (control) scaffolds during 7 days of culture (b).
In summary, a multifunctional scaffold based on PDA and algi-nate was fabricated by 3D printing for the treatment of breast can-cer and tissue repair after surgical therapy. The 3D-printed Alg-PDA scaffolds exhibited analogous modulus to breast tissues. The knotted PDA endowed the Alg-PDA scaffold with excellent pho-tothermal effect, which could kill the cancer cells and efficiently prevent the local recurrence of breast cancer. In addition, the in vivo performance of Alg-PDA scaffolds could be monitored by PAI and MRI. Moreover, human breast cells (MCF-10A) showed a higher proliferation rate on the Alg-PDA scaffold than on the algi-nate scaffold, which indicates the potential ability for breast recon-struction of the Alg-PDA scaffold. The scaffold that is fabricated using simple and biocompatible materials with designed macrop-ores and outstanding photothermal effect might be a potential option for filling the breast cavity resulting from the surgical removal of the breast cancer for the treatment of local recurrence and tissue repair.
This research was funded by the National Natural Science Foundation of China (51573096), Basic Research Program of Shenzhen (JCYJ20170817094407954, JCYJ20180507182413022) and Taipei University of Technology—Shenzhen University Joint Research Program (2018005). The authors also thank the support from the Instrumental Analysis Center of Shenzhen University (Xili Campus).
Appendix A. Supplementary data
 L. De La Cruz, S.A. Blankenship, A. Chatterjee, R. Geha, N. Nocera, B.J. Czerniecki, J. Tchou, C.S. Fisher, Outcomes after oncoplastic breast-conserving surgery in
 D.V. Peralta, Z. Heidari, S. Dash, M.A. Tarr, Hybrid paclitaxel and gold nanorod-loaded human serum albumin nanoparticles for simultaneous chemotherapeutic and photothermal therapy on 4T1 breast cancer cells, ACS Appl. Mater. Interfaces 7 (13) (2015) 7101–7111.
 M.P. Chhaya, F.P.W. Melchels, B.M. Holzapfel, J.G. Baldwin, D.W. Hutmacher, Sustained regeneration of high-volume adipose tissue for breast reconstruction using computer aided design and biomanufacturing, Biomaterials 52 (2015) 551–560.
 F.M. Martín-Saavedra, E. Ruíz-Hernández, A. Boré, D. Arcos, M. Vallet-Regí, N. Vilaboa, Magnetic mesoporous silica spheres for hyperthermia therapy, Acta Biomater. 6 (12) (2010) 4522–4531.  X. Chen, Y. Wu, V.D. Ranjan, Y. Zhang, Three-dimensional electrical conductive scaffold from biomaterial-based carbon microfiber sponge with bioinspired coating for cell proliferation and differentiation, Carbon 134 (2018) 174–182.  M.B. Taskin, R. Xu, H. Gregersen, J.V. Nygaard, F. Besenbacher, M. Chen, Three-dimensional polydopamine functionalized coiled microfibrous scaffolds enhance human mesenchymal stem cells colonization and mild myofibroblastic differentiation, ACS Appl. Mater. Interfaces 8 (25) (2016) 15864–15873.
5-Fluorouracil-related Cardiotoxicity; Findings From Five Randomized Studies of 5-Fluorouracil-based Regimens in Metastatic Colorectal Cancer
This pooled analysis includes de-identified patient-level datasets from 5 randomized studies. Bevacizumab-and panitumumab-containing regimens seem to be associated with a higher risk of cardiac toxicities. Bevacizumab-containing regimens seem to increase the risk of 5-fluorouracil-related ischemic events.
Background: 5-Fluorouracil (5-FU) represents the backbone of systemic therapy regimens of colorectal cancer. The current study aims at evaluating the patterns and predictors of cardiac adverse events associated with various 5-FU-based systemic therapy regimens among patients with metastatic colorectal cancer. Materials and Methods: This pooled analysis includes de-identified patient-level datasets from 5 randomized studies (NCT00272051, NCT00305188, NCT00115765, NCT00364013, and NCT00384176). In order to evaluate factors predicting the development of all cardiac toxicities, arrhythmias, and ischemic events, univariate logistic regression analysis was conducted. Subsequently, factors with P < .05 in univariate analysis were included in multivariate logistic regression analysis. Results: A total of 3223 patients were included in the pooled analysis. A total of 255 (7.9%) patients developed some form of a cardiac toxicity, among which 153 (4.7%) patients developed some form of arrhythmia and 62 (1.9%) patients developed an ischemic event. Within multivariate logistic regression analysis for factors predicting cardiac toxicities, only bevacizumab-containing regimens (P ¼ .002) and panitumumab-containing regimens (P < .001) were predictive for the occurrence of cardiac toxicity. Similarly, within multivariate logistic regression analysis for factors predicting cardiac arrhythmias, only panitumumab-based regimens were predictive of the occurrence of arrhythmias (P < .001). Likewise, within multivariate logistic regression analysis for factors predicting cardiac ischemia, only bevacizumab-containing regimens were predictive of ischemic events (P ¼ .004). Conclusions: Bevacizumab-and panitumumab-containing regimens seem to be associated with a higher risk of cardiac toxicities compared with other 5-FU-based regimens. Bevacizumab-containing regimens seem to increase the risk of 5-FU-related ischemic events, whereas panitumumab-containing regimens seem to increase the risk of arrhythmias.